ICD-10 Support

ICD-10 Support

The ICD-10 Diagnosis Codes For Providers

Easy access to the information you may need

If you’re a provider, you’ll want to get familiar with new billing codes that went into effect October 1, 2015. While sample ICD-9-CM codes have been mapped to the latest ICD-10-CM codes so that coders can become familiar with the new codes prior to the implementation date, the ultimate responsibility for correct coding lies with the provider of services. The codes included in these charts and articles are not intended to be promotional, or to encourage or suggest a use of any drug that is inconsistent with FDA-approved use.

Please refer to the current policy for the latest codes since these codes are subject to change. The codes provided are not intended to be exhaustive. Please consult your ICD-10 code book for additional information.

Click below for an ICD-10 Crosswalk Sample.

ATRIAL FIBRILLATION

ICD-9 Indication ICD-9 Code ICD-10 Indication ICD-10 Code
Atrial Fibrillation 427.31 Paroxysmal atrial fibrillation I48.0
    Persistent atrial fibrillation I48.1
    Chronic atrial fibrillation I48.2
    Unspecified atrial fibrillation I48.91

DEEP VEIN THROMBOSIS

ICD-9 Indication ICD-9 Code ICD-10 Indication ICD-10 Code
Acute venous embolism and thrombosis of deep vessels of lower extremity 453.4X Acute embolism and thrombosis of deep veins of lower extremity I82.4XX
Acute venous embolism and thrombosis of unspecified deep vessels of lower extremity 453.40 Acute embolism and thrombosis of unspecified deep veins of lower extremity I82.40X  
... Deep vein thrombosis NOS   ... Deep vein thrombosis NOS    
... DVT NOS   ... DVT NOS    
    ... right lower extremity I82.401
    ... left lower extremity I82.402
    ... lower extremity, bilateral I82.403
    ... unspecified lower extremity I82.409
Acute venous embolism and thrombosis of deep vessels of proximal lower extremity 453.41 Acute embolism and thrombosis of unspecified femoral vein I82.419*
... Femoral
... Iliac
  Acute embolism and thrombosis of unspecified iliac vein I82.429*
... Popliteal
... Thigh
  Acute embolism and thrombosis of unspecified popliteal vein I82.439*
... Upper leg NOS   Acute embolism and thrombosis of unspecified proximal lower extremity I82.4Y9*
    * Please refer to the ICD-10 book for the lateral and bilateral codes
Acute venous embolism and thrombosis of deep vessels of distal lower extremity 453.42 Acute embolism and thrombosis of unspecified tibial vein I82.449*
... Calf
... Lower leg NOS
... Peroneal
  Acute embolism and thrombosis of other specified deep vein of unspecified lower extremity I82.499*
... Tibial   Acute embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity I82.4Z9*
    * Please refer to the ICD-10 book for the lateral and bilateral codes
Chronic venous embolism and thrombosis of deep vessels of lower extremity 453.5X Chronic embolism and thrombosis of deep veins of lower extremity I82.5XX
Use additional code, if applicable, for associated long-term (current) use of anticoagulants (V58.61) Use additional code, if applicable, for associated long-term (current) use of anticoagulants (Z79.01)
Chronic venous embolism and thrombosis of unspecified deep vessels of lower extremity 453.50 ... unspecified deep veins of right lower extremity I82.501
    ... unspecified deep veins of left lower extremity I82.502
    ... unspecified deep veins of lower extremity, bilateral I82.503
    ... unspecified deep veins of unspecified lower extremity I82.509
    Chronic embolism and thrombosis of other specified deep vein of lower extremity I82.59X
    ... other specified deep vein of right lower extremity I82.591
    ... other specified deep vein of left lower extremity I82.592
    ... other specified deep vein of lower extremity, bilateral I82.593
    ... other specified deep vein of unspecified lower extremity I82.599
Chronic venous embolism and thrombosis of deep vessels of proximal lower extremity 453.51 Chronic embolism and thrombosis of right femoral vein I82.511
... Femoral
... Iliac
  Chronic embolism and thrombosis of left femoral vein I82.512
... Popliteal
... Thigh
  Chronic embolism and thrombosis of femoral vein, bilateral I82.513
... Upper leg NOS   Chronic embolism and thrombosis of unspecified femoral vein I82.519
    Chronic embolism and thrombosis of right iliac vein I82.521
    Chronic embolism and thrombosis of left iliac vein I82.522
    Chronic embolism and thrombosis of iliac vein, bilateral I82.523
    Chronic embolism and thrombosis of unspecified iliac vein I82.529
    Chronic embolism and thrombosis of right popliteal vein I82.531
    Chronic embolism and thrombosis of left popliteal vein I82.532
    Chronic embolism and thrombosis of popliteal vein, bilateral I82.533
    Chronic embolism and thrombosis of unspecified popliteal vein I82.539
    Chronic embolism and thrombosis of unspecified deep veins of right proximal lower extremity I82.5Y1
    Chronic embolism and thrombosis of unspecified deep veins of left proximal lower extremity I82.5Y2
    Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral I82.5Y3
    Chronic embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity I82.5Y9
Chronic venous embolism and thrombosis of deep vessels of distal lower extremity 453.52 Chronic embolism and thrombosis of tibial vein I82.54X
... Calf   ... right tibial vein I82.541
... Lower leg NOS   ... left tibial vein I82.542
... Peroneal   ... tibial vein, bilateral I82.543
... Tibial   ... unspecified tibial vein I82.549
    Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity I82.5ZX
    ... right distal lower extremity I82.5Z1
    ... left distal lower extremity I82.5Z2
    ... distal lower extremity, bilateral I82.5Z3
    ... unspecified deep veins of unspecified distal lower extremity I82.5Z9
Chronic venous embolism and thrombosis of deep veins of upper extremity 453.72 Chronic embolism and thrombosis of deep veins of upper extremity I82.72X
... Brachial vein   ... Brachial vein  
... Radial vein   ... Radial vein  
... Ulnar vein   ... Ulnar vein  
Use additional code, if applicable, for associated long-term (current) use of anticoagulants (V58.61) Use additional code, if applicable, for associated long-term (current) use of anticoagulants (Z79.01)
    ... right upper extremity I82.721
    ... left upper extremity I82.722
    ... upper extremity, bilateral I82.723
    ... unspecified upper extremity I82.729
Acute venous embolism and thrombosis of deep veins of upper extremity 453.82 Acute embolism and thrombosis of deep veins of upper extremity I82.62X
... Brachial vein   ... Brachial vein  
... Radial vein   ... Radial vein  
... Ulnar vein   ... Ulnar vein  
    ... right upper extremity I82.621
    ... left upper extremity I82.622
    ... upper extremity, bilateral I82.623
    ... unspecified upper extremity I82.629

JOINT REPLACEMENT

ICD-9 Indication ICD-9 Code ICD-10 Indication ICD-10 Code
Hip joint replacement V43.64 Presence of unspecified artificial hip joint Z96.649
    ... right artificial hip joint Z96.641
    ... left artificial hip joint Z96.642
    ... artificial hip joint, bilateral Z96.643
Knee joint replacement V43.65 Presence of unspecified artificial knee joint Z96.659
    ... right artificial knee joint Z96.651
    ... left artificial knee joint Z96.652
    ... artificial knee joint, bilateral Z96.653

PULMONARY EMBOLISM

ICD-9 Indication ICD-9 Code ICD-10 Indication ICD-10 Code
Acute cor pulmonale 415.0 Septic pulmonary embolism with acute cor pulmonale I26.01
    Saddle embolus of pulmonary artery with acute cor pulmonale I26.02
    Acute cor pulmonale NOS I26.09
Pulmonary embolism and infarction
Pulmonary (artery) (vein):
... apoplexy
... embolism
... infarction (hemorrhagic)
... thrombosis
415.1X    
Use additional code for associated septic pulmonary embolism, if applicable, 415.12 Code first underlying infection
    Other pulmonary embolism without acute cor pulmonale I26.99
    Acute pulmonary embolism NOS I26.99
    Pulmonary embolism NOS I26.99
    Air embolism following infusion, transfusion and therapeutic injection, initial encounter T80.0XXA
    Complication of other artery following a procedure, not elsewhere classified, initial encounter T81.718A
    Complication of vein following a procedure, not elsewhere classified, initial encounter T81.72XA
    Embolism of cardiac prosthetic devices, implants and grafts, initial encounter T82.817A
    Embolism of vascular prosthetic devices, implants and grafts, initial encounter T82.818A
Septic pulmonary embolism 415.12 Septic pulmonary embolism with acute cor pulmonale I26.01
Code first underlying infection, such as: septicemia (038.0-038.9) Code first underlying infection
    Septic pulmonary embolism without acute cor pulmonale I26.90
    Code first underlying infection
Saddle embolus of pulmonary artery 415.13 Saddle embolus of pulmonary artery with acute cor pulmonale I26.02
    Saddle embolus of pulmonary artery without acute cor pulmonale I26.92
Other pulmonary embolism and infarction 415.19 Other pulmonary embolism with acute cor pulmonale I26.09
    Other pulmonary embolism without acute cor pulmonale I26.99
    Acute pulmonary embolism NOS I26.99
    Pulmonary embolism NOS I26.99
Chronic pulmonary embolism 416.2 Chronic pulmonary embolism I27.82
Use additional code, if applicable, for associated long-term (current) use of anticoagulants (V58.61) Use additional code, if applicable, for associated long-term (current) use of anticoagulants (Z79.01)
Other chronic pulmonary heart diseases
... Pulmonary hypertension NOS
416.8 Other secondary pulmonary hypertension
... Pulmonary hypertension NOS
I27.2
    Code also associated underlying condition
Chronic pulmonary heart disease, unspecified
... Chronic cardiopulmonary disease
416.9 Cor pulmonale (chronic)
... Cor pulmonale NOS
I27.81
... Cor pulmonale (chronic) NOS   Pulmonary heart disease, unspecified I27.9
Other specified diseases of pulmonary circulation 417.8 Other diseases of pulmonary vessels I28.8
Unspecified disease of pulmonary circulation 417.9 Other specified pulmonary heart diseases I27.89
    Disease of pulmonary vessels, unspecified I28.9

For more information on the transition to ICD-10, visit the CMS Web site.

SOURCES
American Medical Association, “2016 The Complete Official Codebook ICD10-CM”

THE INFORMATION CONTAINED IN THIS DOCUMENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND REPRESENTS NO STATEMENT, PROMISE, OR GUARANTEE BY JANSSEN BIOTECH, INC. CONCERNING LEVELS OF REIMBURSEMENT, PAYMENT, OR CHARGE. SIMILARLY, ALL CPT® (©AMA) AND HCPCS CODES ARE SUPPLIED FOR INFORMATIONAL PURPOSES ONLY AND REPRESENT NO STATEMENT, PROMISE, OR GUARANTEE BY JANSSEN BIOTECH, INC. THAT THESE CODES WILL BE APPROPRIATE OR THAT REIMBURSEMENT WILL BE MADE. IT IS NOT INTENDED TO INCREASE OR MAXIMIZE REIMBURSEMENT BY ANY PAYER. WE STRONGLY RECOMMEND THAT YOU CONSULT YOUR PAYER ORGANIZATION WITH REGARD TO ITS REIMBURSEMENT POLICIES.

Indications

XARELTO® is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).

There are limited data on the relative effectiveness of XARELTO® and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.

XARELTO® is indicated for the treatment of deep vein thrombosis (DVT). XARELTO® is indicated for the treatment of pulmonary embolism (PE). XARELTO® is indicated for the reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.

XARELTO® is indicated for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.

Important Safety Information For XARELTO®

WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO® INCREASES THE RISK OF THROMBOTIC EVENTS,
(B) SPINAL/EPIDURAL HEMATOMA

A. Premature discontinuation of XARELTO® increases the risk of thrombotic events

Premature discontinuation of any oral anticoagulant, including XARELTO®, increases the risk of thrombotic events. If anticoagulation with XARELTO® is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.

B. Spinal/epidural hematoma

Epidural or spinal hematomas have occurred in patients treated with XARELTO® who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

  • Use of indwelling epidural catheters
  • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants, see Drug Interactions
  • A history of traumatic or repeated epidural or spinal punctures
  • A history of spinal deformity or spinal surgery
  • Optimal timing between the administration of XARELTO® and neuraxial procedures is not known

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.

CONTRAINDICATIONS

  • Active pathological bleeding
  • Severe hypersensitivity reaction to XARELTO® (eg, anaphylactic reactions)

WARNINGS AND PRECAUTIONS

  • Increased Risk of Thrombotic Events After Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including XARELTO®, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from XARELTO® to warfarin in clinical trials in atrial fibrillation patients. If XARELTO® is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
  • Risk of Bleeding: XARELTO® increases the risk of bleeding and can cause serious or fatal bleeding. Promptly evaluate any signs or symptoms of blood loss and consider the need for blood replacement. Discontinue XARELTO® in patients with active pathological hemorrhage.
    • A specific antidote for rivaroxaban is not available. Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable.
    • Concomitant use of other drugs that impair hemostasis increases the risk of bleeding. These include aspirin, P2Y12 platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, NSAIDs, selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs).
  • Spinal/Epidural Anesthesia or Puncture: When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma, which can result in long-term or permanent paralysis. To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known. An indwelling epidural or intrathecal catheter should not be removed before at least 2 half-lifes have elapsed (ie, 18 hours in young patients aged 20 to 45 years and 26 hours in elderly patients aged 60 to 76 years), after the last administration of XARELTO®. The next XARELTO® dose should not be administered earlier than 6 hours after the removal of the catheter. If traumatic puncture occurs, delay the administration of XARELTO® for 24 hours. Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, monitor frequently to detect any signs or symptoms of neurological impairment, such as midline back pain, sensory and motor deficits (numbness, tingling, or weakness in lower limbs), or bowel and/or bladder dysfunction. Instruct patients to immediately report if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.
  • Use in Patients With Renal Impairment:
    • Nonvalvular Atrial Fibrillation: Periodically assess renal function as clinically indicated (ie, more frequently in situations in which renal function may decline) and adjust therapy accordingly. Consider dose adjustment or discontinuation of XARELTO® in patients who develop acute renal failure while on XARELTO®.
    • Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE: Avoid the use of XARELTO® in patients with CrCl <30 mL/min due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population.
    • Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery: Avoid the use of XARELTO® in patients with CrCl <30 mL/min due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 30 to 50 mL/min. Patients who develop acute renal failure while on XARELTO® should discontinue the treatment.
  • Use in Patients With Hepatic Impairment: No clinical data are available for patients with severe hepatic impairment. Avoid use of XARELTO® in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment or with any hepatic disease associated with coagulopathy, since drug exposure and bleeding risk may be increased.
  • Use With P-gp and Strong CYP3A4 Inhibitors or Inducers: Avoid concomitant use of XARELTO® with combined P-gp and strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, indinavir, and conivaptan). Avoid concomitant use of XARELTO® with drugs that are P-gp and strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin, St. John’s wort).
  • Risk of Pregnancy-Related Hemorrhage: In pregnant women, XARELTO® should be used only if the potential benefit justifies the potential risk to the mother and fetus. XARELTO® dosing in pregnancy has not been studied. The anticoagulant effect of XARELTO® cannot be monitored with standard laboratory testing and is not readily reversed. Promptly evaluate any signs or symptoms suggesting blood loss (eg, a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress).
  • Patients With Prosthetic Heart Valves: The safety and efficacy of XARELTO® have not been studied in patients with prosthetic heart valves. Therefore, use of XARELTO® is not recommended in these patients.
  • Acute PE in Hemodynamically Unstable Patients/Patients Who Require Thrombolysis or Pulmonary Embolectomy: Initiation of XARELTO® is not recommended acutely as an alternative to unfractionated heparin in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

DRUG INTERACTIONS

  • Avoid concomitant use of XARELTO® with other anticoagulants due to increased bleeding risk, unless benefit outweighs risk. Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs.
  • XARELTO® should not be used in patients with CrCl 15 to <80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors (eg, diltiazem, verapamil, dronedarone, and erythromycin) unless the potential benefit justifies the potential risk.

USE IN SPECIFIC POPULATIONS

  • Pregnancy Category C: XARELTO® should be used during pregnancy only if the potential benefit justifies the potential risk to mother and fetus. There are no adequate or well-controlled studies of XARELTO® in pregnant women, and dosing for pregnant women has not been established. Use XARELTO® with caution in pregnant patients because of the potential for pregnancy-related hemorrhage and/or emergent delivery with an anticoagulant that is not readily reversible. The anticoagulant effect of XARELTO® cannot be reliably monitored with standard laboratory testing.
  • Labor and Delivery: Safety and effectiveness of XARELTO® during labor and delivery have not been studied in clinical trials.
  • Nursing Mothers: It is not known if rivaroxaban is excreted in human milk.
  • Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
  • Females of Reproductive Potential: Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician.

OVERDOSAGE

  • Discontinue XARELTO® and initiate appropriate therapy if bleeding complications associated with overdosage occur. A specific antidote for rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of XARELTO® overdose may be considered. Due to the high plasma protein binding, rivaroxaban is not dialyzable.

ADVERSE REACTIONS IN CLINICAL STUDIES

  • The most common adverse reactions with XARELTO® were bleeding complications.

Please see full Prescribing Information, including Boxed WARNINGS.

059086-160829